Sự đồng xuất hiện của chứng parkinson và sa sút trí tuệ trong thực hành lâm sàng

Battistin L, Cagnin A (2010) Vascular cognitive disorder. A biological and clinical overview. Neurochem Res 35:1933–1938 Bohnen NI, Kaufer DI, Hendrickson R et al (2006) Cognitive correlates of cortical cholinergic denervation in Parkinson’s disease and parkinsonian dementia. J Neurol 253:242–247 Bronnick K, Emre M, Lane R et al (2007) Profile of cognitive impairment in dementia associated with Parkinson’s disease compared with Alzheimer’s disease. J Neurol Neurosurg Psychiatry 78:1064–1068 Compta Y, Parkkinen L, O’Sullivan SS et al (2011) Lewy- and Alzheimer-type pathologies in Parkinson’s disease dementia: which is more important? Brain 134:1493–1505 Cummings J, Litvan I (2000) Neuropsychiatric aspects of corticobasal degeneration. Adv Neurol 82:147–152 Elbaz A, Bower JH, Maraganore DM et al (2002) Risk tables for parkinsonism and Parkinson’s disease. J Clin Epidemiol 55:25–31 Erkinjuntti T, Kurz A, Gauthier S et al (2002) Efficacy of galantamine in probable vascular dementia and Alzheimer’s disease combined with cerebrovascular disease: a randomised trial. Lancet 359:1283–1290 Forsaa EB, Larsen JP, Wentzel-Larsen T et al (2010) What predicts mortality in Parkinson disease? A prospective population-based long-term study. Neurology 75:1270–1276 Geser F, Wenning GK, Poewe W et al (2005) How to diagnose dementia with Lewy bodies: state of the art. Mov Disord 20(Suppl 12):11–20 Gilman S, Koeppe RA, Nan B et al (2010) Cerebral cortical and subcortical cholinergic deficits in parkinsonian syndromes. Neurology 74:1416–1423 Grimes DA, Lang AE, Bergeron CB (1999) Dementia as the most common presentation of cortical-basal ganglionic degeneration. Neurology 53:1969–1974 Hamilton R, Patel S, Lee EB et al (2010) Lack of shunt response in suspected idiopathic normal pressure hydrocephalus with Alzheimer disease pathology. Ann Neurol 68:535–540 Hardie RJ, Lees AJ (1988) Neuroleptic-induced Parkinson’s syndrome: clinical features and results of treatment with levodopa. J Neurol Neurosurg Psychiatry 51:850–854 Kehagia AA, Barker RA, Robbins TW (2010) Neuropsychological and clinical heterogeneity of cognitive impairment and dementia in patients with Parkinson’s disease. Lancet Neurol 9:1200–1213 Kuo SH, Kenney C, Jankovic J (2008) Bilateral pedunculopontine nuclei strokes presenting as freezing of gait. Mov Disord 23:616–619 Liepelt I, Gaenslen A, Godau J et al (2010) Rivastigmine for the treatment of dementia in patients with progressive supranuclear palsy: clinical observations as a basis for power calculations and safety analysis. Alzheimers Dement 6:70–74 Liepelt I, Maetzler W, Blaicher HP et al (2007) Treatment of dementia in parkinsonian syndromes with cholinesterase inhibitors. Dement Geriatr Cogn Disord 23:351–367 Liepelt I, Reimold M, Maetzler W et al (2009) Cortical hypometabolism assessed by a metabolic ratio in Parkinson’s disease primarily reflects cognitive deterioration-[(18)F]FDG-PET. Mov Disord 24:1504–1511 Lippa CF, Duda JE, Grossman M et al (2007) DLB and PDD boundary issues: diagnosis, treatment, molecular pathology, and biomarkers. Neurology 68:812–819 Litvan I, Phipps M, Pharr VL et al (2001) Randomized placebo-controlled trial of donepezil in patients with progressive supranuclear palsy. Neurology 57:467–473 Maetzler W, Liepelt I, Berg D (2009) Progression of Parkinson’s disease in the clinical phase: potential markers. Lancet Neurol 8:1158–1171 Maetzler W, Liepelt I, Reimold M et al (2009) Cortical PIB binding in Lewy body disease is associated with Alzheimer-like characteristics. Neurobiol Dis 34:107–112 Maetzler W, Nagele T, Gasser T et al (2007) Acute parkinsonism with corresponding lesions in the basal ganglia after heroin abuse. Neurology 68:414 Maetzler W, Schmid B, Synofzik M et al (2010) The CST3 BB genotype and low cystatin C cerebrospinal fluid levels are associated with dementia in Lewy body disease. J Alzheimers Dis 19:937–942 Maetzler W, Stoycheva V, Schmid B et al (2010) Neprilysin activity in cerebrospinal fluid is associated with dementia and amyloid-beta42 levels in Lewy body disease. J Alzheimers Dis 22:933–938 McKeith I, Mintzer J, Aarsland D et al (2004) Dementia with Lewy bodies. Lancet Neurol 3:19–28 McKeith IG, Dickson DW, Lowe J et al (2005) Diagnosis and management of dementia with Lewy bodies. Third report of the DLB consortium. Neurology 65:1863–1872 Mummenthaler M (1987) Behebbare und vermeidbare Demenzen. Schweiz Med Wochenschr 117:964–967 Nicolai S, Mirelman A, Herman T et al (2010) Improvement of balance after audio-biofeedback. A 6-week intervention study in patients with progressive supranuclear palsy. Z Gerontol Geriatr 43:224–228 O’Sullivan SS, Massey LA, Williams DR et al (2008) Clinical outcomes of progressive supranuclear palsy and multiple system atrophy. Brain 131:1362–1372 Ott A, Breteler MM, Van Harskamp F et al (1995) Prevalence of Alzheimer’s disease and vascular dementia: association with education. The Rotterdam study. Br Med J (Clin Res) 10:970–973 Pendlebury ST, Cuthbertson FC, Welch SJ et al (2010) Underestimation of cognitive impairment by Mini-Mental State Examination versus the Montreal Cognitive Assessment in patients with transient ischemic attack and stroke: a population-based study. Stroke 41:1290–1293 Penn RD, Linninger A (2009) The physics of hydrocephalus. Pediatr Neurosurg 45:161–174 Saczynski JS, Sigurdsson S, Jonsdottir MK et al (2009) Cerebral infarcts and cognitive performance: importance of location and number of infarcts. Stroke 40:677–682 Schneider JA, Arvanitakis Z, Bang W et al (2007) Mixed brain pathologies account for most dementia cases in community-dwelling older persons. Neurology 69:2197–2204 Seijo-Martinez M, Castro Del Rio M, Rodriguez Alvarez J et al (2011) Prevalence of parkinsonism and Parkinson’s disease in the Arosa Island (Spain): a community-based door-to-door survey. J Neurol Sci 304:49–54 Shelley BP, Hodges JR, Kipps CM et al (2009) Is the pathology of corticobasal syndrome predictable in life? Mov Disord 24:1593–1599 Sinforiani E, Banchieri L, Zucchella C et al (2004) Cognitive rehabilitation in Parkinson’s disease. Arch Gerontol Geriatr 9(Suppl):387–391 Srulijes K, Mallien G, Bauer S et al (2011) In vivo comparison of Richardson’s syndrome and progressive supranuclear palsy-parkinsonism. J Neural Transm 118:1191–1197 Tarnaris A, Toma AK, Chapman MD et al (2011) Use of cerebrospinal fluid amyloid-beta and total tau protein to predict favorable surgical outcomes in patients with idiopathic normal pressure hydrocephalus. J Neurosurg 115:145–150 Trenkwalder C, Schwarz J, Gebhard J et al (1995) Starnberg trial on epidemiology of Parkinsonism and hypertension in the elderly. Prevalence of Parkinson’s disease and related disorders assessed by a door-to-door survey of inhabitants older than 65 years. Arch Neurol 52:1017–1022 Turner ST, Fornage M, Jack CR et al (2009) Genomic susceptibility Loci for brain atrophy, ventricular volume, and leukoaraiosis in hypertensive sibships. Arch Neurol 66:847–857 Villarejo A, Benito-Leon J, Trincado R et al (2011) Dementia-associated mortality at thirteen years in the NEDICES cohort study. J Alzheimers Dis (in press) Wenning GK, Litvan I, Tolosa E (2011) Milestones in atypical and secondary parkinsonisms. Mov Disord 26:1083–1095 Williams DR, Lees AJ (2009) Progressive supranuclear palsy: clinicopathological concepts and diagnostic challenges. Lancet Neurol 8:270–279